Published on: 15 July 2013
Skip to main content
The recently-published SITC Combination Immunotherapy Task Force white paper, entitled “Combination immunotherapy: a road map” (Ott et al.), aims to identify the most promising prospects for combination therapy and address challenges associated with combinatorial approaches. Building on previous work on combination immunotherapy, this article is the first to address the use of mouse models, safety considerations in early clinical testing, the need for innovative early phase clinical trial designs, and appropriate safety and efficacy endpoints for early phase clinical trials, all in the specific setting of combination immunotherapy.
Guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma were also recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
Immunotherapies are best known to be responsible for thrombotic microangiopathy. However, immune interstitial nephritis has been described in a patient treated…
Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas and Stephane Dalle
Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than…
Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride and Andrew S. Kraft
The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163.
Michael C. Topf, Madalina Tuluc, Larry A. Harshyne and Adam Luginbuhl
Combination therapy with anti-cytotoxic T-lymphocyteassociated-protein 4 (CTLA-4) and anti-programmed death ligand 1 (PD-L1) monoclonal antibodies holds incredible potential for the…
Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner
and Ben C. Creelan
Immune checkpoint blockade using monoclonal antibodies have been approved by the US Food and Drug Administration (FDA) to treat patients with…
Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon
and Patrick A. Ott
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant…
Frederick L. Locke, Claudio Anasetti for the Moffitt Immunotherapy Working Group and the Immune Cell Therapy (ICE-T) Program
Over the last decade, immunological therapies have been investigated for the treatment of many types of carcinomas with FDA approvals of…
Laura E. Johnson, Brian M. Olson and Douglas G. McNeel
As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily…
Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger
Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs
and a growing list of approved immune-based agents…
James L. Gulley, Elizabeth A. Repasky, Laura S. Wood and Lisa H.
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 19 August 2014
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.
Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!
For more information please email email@example.com, call +1 414 271-2456, or visit http://sitcancer.org/journal.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.